Middle East and Africa lung cancer screening software market is projected to register a CAGR of 14.8% in the forecast period of 2020 to 2027. The new market report contains data for historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Middle East and Africa Lung Cancer Screening Software Market, By Mode of Delivery (Cloud Based Solutions, On-premise Solutions, & Web Based Solutions), Type (Computer-Assisted Screening and Traditional Screening), Product (Lung Cancer Screening Radiology Solution, Lung Cancer Screening Patient Management Software, Nodule Management Software, Data Collection and Reporting, Patient Coordination and Workflow, Lung Nodule Computer Aided Detection, Pathology and Cancer Staging, Statistical Audit Reporting, Screening PACs, Practice Management & Audit Log Tracking), Application (Non-Small Cell Lung Cancer (NSCLC) & Small Cell Lung Cancer (SCLC), Platform (Standalone, Integrated), Purchase Mode (Institutional & Individual), End User (Oncology Centers, Hospitals, Ambulatory Surgical Centers & Others), Distribution Channel (Direct Tenders, Third Party Distributor), Country (South Africa, Saudi Arabia, UAE, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2027
Some of the major factors contributing to the growth of the Middle East and Africa lung cancer screening software market are:
- Increasing awareness regarding the benefits of early diagnosis and frequent screening
- Technological advancement in field of healthcare
Market Players:
The key market players for Middle East and Africa lung cancer screening software market are listed below:
- Medtronic
- PenRad Technologies Inc.
- Koninklijke Philips N.V.
- Volpara Solutions Limited
- Lungview
- Siemens Healthcare Private Limited
- Thynk Health, Eon
- Nuance Communications, Inc.
- MeVis Medical Solutions AG
- Vital Images (A Subsidiary of Canon Group company)
- HealthMyne
- Optellum Ltd
- Coreline Soft, Co., Ltd.
- MyCareWare
- ProVation Medical, Inc.
